Cargando…
HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation
BACKGROUND & AIMS: The contribution of abnormal metabolic targets to hepatocellular carcinoma (HCC) progression and the associated regulatory mechanisms are attractive research areas. High-density lipoprotein binding protein (HDLBP) is an important transporter that protects cells from excessive...
Autores principales: | Yuan, Jingsheng, Lv, Tao, Yang, Jian, Wu, Zhenru, Yan, Lvnan, Yang, Jiayin, Shi, Yujun, Jiang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772558/ https://www.ncbi.nlm.nih.gov/pubmed/36244648 http://dx.doi.org/10.1016/j.jcmgh.2022.10.005 |
Ejemplares similares
-
HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma
por: Yuan, Jingsheng, et al.
Publicado: (2022) -
A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients
por: Yuan, Jingsheng, et al.
Publicado: (2022) -
TRIM22 promotes the proliferation of glioblastoma cells by activating MAPK signaling and accelerating the degradation of Raf-1
por: Fei, Xiaowei, et al.
Publicado: (2023) -
Comprehensive Molecular Analysis Identified an SRSF Family-Based Score for Prognosis and Therapy Efficiency Prediction in Hepatocellular Carcinoma
por: Yuan, Jingsheng, et al.
Publicado: (2022) -
Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
por: Zhuang, Lei, et al.
Publicado: (2017)